|
Manifaxine (GW-320,659) is a drug developed by GlaxoSmithKline through structural modification of radafaxine, one of the major active metabolites of bupropion. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was researched for treatment of ADHD and obesity and was shown to be safe, reasonably effective and well tolerated for both applications,〔DeVeaugh-Geiss J, Conners CK, Sarkis EH, Winner PK, Ginsberg LD, Hemphill JM, Laurenza A, Barrows CE, Webster CJ, Stotka CJ, Asgharnejad M. GW320659 for the treatment of attention-deficit/hyperactivity disorder in children. ''Journal of the American Academy of Child and Adolescent Psychiatry''. 2002 Aug;41(8):914-20. PMID 12162627〕〔Spraggs CF, Pillai SG, Dow D, Douglas C, McCarthy L, Manasco PK, Stubbins M, Roses AD. Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. ''Pharmacogenetics and Genomics''. 2005 Dec;15(12):883-9. PMID 16272960〕 but no results have been reported following these initial trials and its current status is unclear. ==See also== * Phenmetrazine * Radafaxine * Hydroxybupropion * G-130 * 2-Phenyl-3,6-dimethylmorpholine 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Manifaxine」の詳細全文を読む スポンサード リンク
|